Sargent Bickham Lagudis’s Fulgent Genetics FLGT Stock Holding History

Sargent Bickham Lagudis’s Portfolio FLGT Stock Details FLGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,222	Closed	-$85K	–	1065
2022 Q3	$85K	Buy	+2,222	New	+$111K	0.01%	336

Other funds holding FLGT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Sargent Bickham Lagudis's FLGT Position: Q4 2022 in Review

Sargent Bickham Lagudis sold out of Fulgent Genetics (FLGT) in Q4 2022, closing a stake of 2,222 shares — an estimated $85K sold.

Sargent Bickham Lagudis first reported a position in FLGT in Q3 2022 and held it in 1 quarter. The position peaked at $85K in Q3 2022. 224 funds tracked by Wall St. Rank hold FLGT as of Q4 2022.

Sargent Bickham Lagudis reported no remaining Fulgent Genetics position as of Q4 2022 after selling out during the quarter.
Sargent Bickham Lagudis sold 2,222 Fulgent Genetics shares in Q4 2022, an estimated $85K.
Sargent Bickham Lagudis first reported a position in Fulgent Genetics in Q3 2022 and held it in 1 quarter.
Sargent Bickham Lagudis's Fulgent Genetics position peaked at $85K in Q3 2022.
224 funds tracked by Wall St. Rank held Fulgent Genetics as of Q4 2022.

Based on Sargent Bickham Lagudis's 13F filing for Q4 2022, filed 23 Jan 2023.